ID: ALA261831

Max Phase: Preclinical

Molecular Formula: C16H19N3O3S

Molecular Weight: 333.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(CCCCCSc1nc(-c2ccccc2)cc(=O)[nH]1)NO

Standard InChI:  InChI=1S/C16H19N3O3S/c20-14(19-22)9-5-2-6-10-23-16-17-13(11-15(21)18-16)12-7-3-1-4-8-12/h1,3-4,7-8,11,22H,2,5-6,9-10H2,(H,19,20)(H,17,18,21)

Standard InChI Key:  YOKJODNAAKQIBZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 333.41

Molecular Weight (Monoisotopic): 333.1147

AlogP: 2.59

#Rotatable Bonds: 8

Polar Surface Area: 95.08

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.67

CX Basic pKa: 0.49

CX LogP: 2.14

CX LogD: 1.97

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.23

Np Likeness Score: -1.18

References

1. Mai A, Massa S, Rotili D, Pezzi R, Bottoni P, Scatena R, Meraner J, Brosch G..  (2005)  Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates.,  15  (21): [PMID:16165353] [10.1016/j.bmcl.2005.07.081]

2. Mai A, Massa S, Rotili D, Simeoni S, Ragno R, Botta G, Nebbioso A, Miceli M, Altucci L, Brosch G..  (2006)  Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.,  49  (20): [PMID:17004718] [10.1021/jm0605536]

3. Paris M, Porcelloni M, Binaschi M, Fattori D..  (2008)  Histone deacetylase inhibitors: from bench to clinic.,  51  (6): [PMID:18247554] [10.1021/jm7011408]

Source

Source(1):

• Scientific Literature